Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment. Saito Y, Takekuma Y, Takeshita T, Noguchi T, et al. Anticancer Res 2022;42:3693-3700.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Saito Y, Takekuma Y, Takeshita T, Noguchi T, et al. Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment. Anticancer Res 2022;42:3693-3700.
PMID: 35790277